Guidelines for diagnosis and treatment of Hunter syndrome for clinicians in Latin America

Genetics and Molecular Biology

Volumn 37, Issue 2, 2014, Pages 315-329

  Giugliani, Roberto ^a,b,c   Villarreal, Martha Luz Solano ^d   Araceli Arellano Valdez, C ^e   Hawilou, Antonieta Mahfoud ^f   Guelbert, Norberto ^g   Garzón, Luz Norela Correa ^h   Martins, Ana Maria ⁱ   Acosta, Angelina ^j   Cabello, Juan Francisco ^k   Lemes, Aída ^l   Santos, Mara Lucia Schmitz Ferreira ^m   Amartino, Hernán ⁿ  

^a Serviço de Génetica Médica Hospital de Clinicas de Porto Alegre   (Colombia)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Instituto Nacional de Genética Médica Populacional   (Colombia)

^d Asociación Colombiana de Infectología   (Colombia)

^e INSTITUTO MEXICANO DEL SEGURO SOCIAL   (Mexico)

^f Instituto Internacional de Estudios Avanzados IDEA   (Venezuela)

^g Hospital de Ninos de la Santisima Trinidad   (Argentina)

^h La Misericordia University Hospital   (Colombia)

ⁱ FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^j FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^k UNIVERSITY OF CHILE   (Chile)

^l Hospital Italiano Montevideo   (Uruguay)

^m HOSPITAL PEQUENO PRÍNCIPE   (Brazil)

ⁿ UNIVERSIDAD AUSTRAL   (Argentina)

more..

Author keywords

Enzyme replacement therapy; Hunter syndrome; Iduronate 2 sulfatase; Lysosomal disease; Treatment guidelines

Indexed keywords

ANTIHISTAMINIC AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; GLYCOSAMINOGLYCAN; HEPARIN COFACTOR II; IDURONATE 2 SULFATASE; OXYGEN; PARACETAMOL; PLACEBO; THROMBIN;

ANAPHYLAXIS; BEHAVIOR DISORDER; BONE DYSPLASIA; CLINICAL EVALUATION; CLINICAL PRACTICE; COGNITIVE DEFECT; DRUG TOLERABILITY; EAR INFECTION; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME DEFICIENCY; ENZYME REPLACEMENT; FACE DYSMORPHIA; GENE MUTATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; HUNTER SYNDROME; I2S GENE; INFUSION RELATED REACTION; INGUINAL HERNIA; INTERPERSONAL COMMUNICATION; LIVER SIZE; MACROCEPHALY; MOLECULAR DIAGNOSIS; PATIENT MONITORING; PHENOTYPE; PRACTICE GUIDELINE; RASH; RESPIRATORY FUNCTION; RESPIRATORY TRACT INFECTION; REVIEW; SCREENING; SHORT STATURE; SLEEP DISORDERED BREATHING; SOCIAL SUPPORT; SOUTH AND CENTRAL AMERICA; SPLEEN SIZE; WALKING; WHEEZING;

EID: 84907914291     PISSN: 14154757     EISSN: 16784685     Source Type: Journal    
DOI: 10.1590/S1415-47572014000300003     Document Type: Review

References (53)

1. Alcalde-Martin C, Muro-Tudelilla JM, Cancho-Candela R, Gutierrez-Solana LG, Pintos-Morell G, Marti-Herrero M, Munguira-Aguado P and Galan-Gomez E (2010) First experience of enzyme replacement therapy with idursulfase in Spanish patients with Hunter syndrome under 5 years of age: Case observations from the Hunter Outcome Survey (HOS). Eur J Med Genet 53:371-377.
2. American Thoracic Society (2002) ATS statement: guidelines for the six-minute walk test. Am J Respir Crit Care Med 166:111-117.
3. Ballabio A and Gieselmann V (2009) Lysosomal disorders: from storage to cellular damage. Biochim Biophys Acta 1793:684-696.
4. Barbier AJ, Bielefeld B, Whiteman DA, Natarajan M, Pano A and Amato DA (2013) The relationship between anti-idursulfase antibody status and safety and efficacy outcomes in attenuated mucopolysaccharidosis II patients aged 5 years and older treated with intravenous idursulfase. Mol Genet Metab 110:303-310.
5. Beck M (2011) Mucopolysaccharidosis type II (Hunter syndrome): clinical picture and treatment. Curr Pharm Bio-technol 12:861-866.
6. Braunlin EA, Harmatz PR, Scarpa M, Furlanetto B, Kampmann C, Loehr JP, Ponder KP, Roberts WC, Rosenfeld HM and Giugliani R (2011) Cardiac disease in patients with muco-polysaccharidosis: presentation, diagnosis and management. J Inherit Metab Dis 34:1183-1197.
7. Burton BK and Whiteman DA (2011) Incidence and timing of infusion-related reactions in patients with mucopoly-saccharidosis type II (Hunter syndrome) on idursulfase therapy in the real-world setting: a perspective from the Hunter Outcome Survey (HOS). Mol Genet Metab 103:113-120.
8. Burton BK, Guffon N, Roberts J, van der Ploeg AT and Jones SA (2010) Home treatment with intravenous enzyme replacement therapy with idursulfase for mucopolysaccharidosis type II - data from the Hunter Outcome Survey. Mol Genet Metab 101:123-129.
9. Civallero G, Michelin K, de Mari J, Viapiana M, Burin M, Coelho JC and Giugliani R (2006) Twelve different enzyme assays on dried-blood filter paper samples for detection of patients with selected inherited lysosomal storage diseases. Clin Chim Acta 372:98-102.
10. Clarke LA (2008) Idursulfase for the treatment of mucopoly-saccharidosis II. Expert Opin Pharmacother 9:311-317.
11. Clarke LA, Winchester B, Giugliani R, Tylki-Szymanska A and Amartino H (2012) Biomarkers for the mucopoly-saccharidoses: discovery and clinical utility. Mol Genet Metab 106:395-402.
12. de Jong JG, Wevers RA, Laarakkers C and Poorthuis BJ (1989) Dimethylmethylene blue-based spectrophotometry of gly-cosaminoglycans in untreated urine: A rapid screening procedure for mucopolysaccharidoses. Clin Chem 35:1472-1477.
13. Dean CJ, Bockmann MR, Hopwood JJ, Brooks DA and Meikle PJ (2006) Detection of mucopolysaccharidosis type II by measurement of iduronate-2-sulfatase in dried blood spots and plasma samples. Clin Chem 52:643-649.
14. Dickson PI (2009) Novel treatments and future perspectives: outcomes of intrathecal drug delivery. Int J Clin Pharmacol Ther 47 Suppl 1:S124-127.
15. Ferrari S, Ponzin D, Ashworth JL, Fahnehjelm KT, Summers CG, Harmatz PR and Scarpa M (2011) Diagnosis and management of ophthalmological features in patients with muco-polysaccharidosis. Br J Ophthalmol 95:613-619.
16. Froissart R, Moreira da Silva I, Guffon N, Bozon D and Maire I (2002) Mucopolysaccharidosis type II - genotype/pheno-type aspects. Acta Paediatr 91:82-87.
17. Giugliani R, Hwu W, Tylki-Szymanska A, Whiteman D and Pano A (2013) A multi-center, open-label study evaluating safety and clinical outcomes in young children (1.4-7.5 years) with Hunter syndrome receiving idursulfase enzyme replacement therapy. Genet Med, Epub Ahead of Print.
18. Greenwald BJ (2010) Clinical practice guidelines for pediatric constipation. J Am Acad Nurse Pract 22:332-338.
19. Guelbert N, Amartino H, Arberas C, Azar N, Bay L, Faiboim A, Fernandez MC, Giner A, Ilari R, Marchione D, et al. (2011) Guideline for diagnosis, follow-up and treatment of muco-polysaccharidoses type II or Hunter disease. Arch Argent Pediatr 109:175-181 [in Spanish].
20. Guffon N, Bertrand Y, Forest I, Fouilhoux A and Froissart R (2009) Bone marrow transplantation in children with Hunter syndrome: outcome after 7 to 17 years. J Pediatr 154:733-737.
21. Holt J, Poe MD and Escolar ML (2011a) Early clinical markers of central nervous system involvement in mucopoly-saccharidosis type II. J Pediatr 159:320-326.e2.
22. Holt JB, Poe MD and Escolar ML (2011b) Natural progression of neurological disease in mucopolysaccharidosis type II. Pediatrics 127:e1258-e1265.
23. Jurecka A, Krumina Z, Zuber Z, Rozdzynska-Swiatkowska A, Kloska A, Czartoryska B and Tylki-Szymanska A (2012) Mucopolysaccharidosis type II in females and response to enzyme replacement therapy. Am J Med Genet A 158A:450-454.
24. Keilmann A, Nakarat T, Bruce IA, Molter D and Malm G (2012) Hearing loss in patients with mucopolysaccharidosis II: data from HOS - the Hunter Outcome Survey.J Inherit Metab Dis 35:343-353.
25. Langford-Smith KJ, Mercer J, Petty J, Tylee K, Church H, Roberts J, Moss G, Jones S, Wynn R, Wraith JE, et al. (2011) Heparin cofactor II-thrombin complex and dermatan sul-phate:chondroitin sulphate ratio are biomarkers of short- and long-term treatment effects in mucopolysaccharide diseases. J Inherit Metab Dis 34:499-508.
26. Link B, Henseman L, Pinto L, Beck M, Guffon N, on behalf of the HOS investigators (2010) Orthopedic manifestations in patients with mucopolysaccharidosis type II (Hunter syndrome) enrolled in the Hunter Outcome Survey. Orthop Rev (Pavia) 2:e16.
27. Liu KL (1980) The oral signs of Hurler-Hunter syndrome: report of four cases. ASDC J Dent Child 47:122-127.
28. Lu JZ, Boado RJ, Hui EK, Zhou QH and Pardridge WM (2011) Expression in CHO cells and pharmacokinetics and brain uptake in the Rhesus monkey of an IgG-iduronate-2-sulfatase fusion protein. Biotechnol Bioeng 108:1954-64.
29. Martin R, Beck M, Eng C, Giugliani R, Harmatz P, Munoz V and Muenzer J (2008) Recognition and diagnosis of mucopoly-saccharidosis II (Hunter syndrome). Pediatrics 121:e377-e386.
30. Mendelsohn NJ, Harmatz P, Bodamer O, Burton BK, Giugliani R, Jones SA, Lampe C, Malm G, Steiner RD and Parini R (2010) Importance of surgical history in diagnosing muco- polysaccharidosis type II (Hunter syndrome): Data from the Hunter Outcome Survey. Genet Med 12:816-822.
31. Miebach E (2009) Management of infusion-related reactions to enzyme replacement therapy in a cohort of patients with mucopolysaccharidosis disorders. Int J Clin Pharmacol Ther 47 (suppl 1):S100-S106.
32. Milligan A, Hughes D, Goodwin S, Richfield L and Mehta A (2006) Intravenous enzyme replacement therapy: better in home or hospital? Br J Nurs 15:330-333.
33. Muenzer J, Wraith JE, Beck M, Giugliani R, Harmatz P, Eng CM, Vellodi A, Martin R, Ramaswami U, Gucsavas-Calikoglu M, et al. (2006) A phase II/III clinical study of enzyme replacement therapy with idursulfase in mucopoly-saccharidosis II (Hunter syndrome). Genet Med 8:465-473.
34. Muenzer J, Gucsavas-Calikoglu M, McCandless SE, Schuetz TJ and Kimura A (2007) A phase I/II clinical trial of enzyme replacement therapy in mucopolysaccharidosis II (Hunter syndrome). Mol Genet Metab 90:329-337.
35. Muenzer J, Beck M, Eng CM, Escolar ML, Giugliani R, Guffon NH, Harmatz P, Kamin W, Kampmann C, Koseoglu ST, et al. (2009) Multidisciplinary management of Hunter syndrome. Pediatrics 124:e1228-e1239.
36. Muenzer J, Beck M, Giugliani R, Suzuki Y, Tylki-Szymanska A, Valayannopoulos V, Vellodi A and Wraith JE (2011) Idur-sulfase treatment of Hunter syndrome in children younger than 6 years: results from the Hunter Outcome Survey. Genet Med 13:102-109.
37. Muenzer J, Bodamer O, Burton B, Clarke L, Frenking GS, Giu-gliani R, Jones S, Rojas MV, Scarpa M, Beck M, et al. (2012) The role of enzyme replacement therapy in severe Hunter syndrome - an expert panel consensus. Eur J Pediatr 171:181-188.
38. Neufeld EF and Muenzer J (2001) The mucopolysaccharidoses. In: Scriver CR, Beaudet AL, Sly WS and Valle D (eds) The Metabolic and Molecular Bases of Inherited Disease, Volume III. 8th edition. McGraw-Hill, New York, pp 3421-3452.
39. Peck JE (1984) Hearing loss in Hunter’s syndrome - Muco-polysaccharidosis II. Ear Hear 5:243-246.
40. Pinto R, Caseiro C, Lemos M, Lopes L, Fontes A, Ribeiro H, Pinto E, Silva E, Rocha S, Marcao A, et al. (2004) Prevalence of lysosomal storage diseases in Portugal. Eur J Hum Genet 12:87-92.
41. Prasad VK and Kurtzberg J (2010) Transplant outcomes in muco-polysaccharidoses. Semin Hematol 47:59-69.
42. Randall DR, Colobong KE, Hemmelgarn H, Sinclair GB, Hetty E, Thomas A, Bodamer OA, Volkmar B, Fernhoff PM, Casey R, et al. (2008) Heparin cofactor II-thrombin complex: a biomarker of MPS disease. Mol Genet Metab 94:456-461.
43. Scarpa M (2011) Mucopolysaccharidosis type II. In: Pagon R, Bird T, Dolan C and Stephens K (eds) GeneReviews 1993-2007. University of Washington, Seattle, E-book. Available at: www.ncbi.nlm.nih.gov/books/NBK1274/, accessed May 1, 2014.
44. Scarpa M, Almassy Z, Beck M, Bodamer O, Bruce IA, De Meir-leir L, Guffon N, Guillen-Navarro E, Hensman P, Jones S, et al. (2011) Mucopolysaccharidosis type II: European recommendations for the diagnosis and multidisciplinary management of a rare disease. Orphanet J Rare Dis 6:72.
45. Schulze-Frenking G, Jones SA, Roberts J, Beck M and Wraith JE (2011) Effects of enzyme replacement therapy on growth in patients with mucopolysaccharidosis type II. J Inherit Metab Dis 34:203-208.
46. ® (idursulfase) solution for intravenous infusion [prescribing information]. Cambridge, MA: Shire Human Genetic Therapies, Inc.
47. Tuschl K, Gal A, Paschke E, Kircher S and Bodamer OA (2005) Mucopolysaccharidosis type II in females: case report and review of literature. Pediatr Neurol 32:270-272.
48. Tylki-Szymanska A, Jurecka A, Zuber Z, Rozdzynska A, Maru-cha J and Czartoryska B (2012) Enzyme replacement therapy for mucopolysaccharidosis II from 3 months of age: a 3-year follow-up. Acta Paediatr 101:e42-e47.
49. Vellodi A, Young E, New M, Pot-Mees C and Hugh-Jones K (1992) Bone marrow transplantation for Sanfilippo disease type B. J Inherit Metab Dis 15:911-918.
50. Vellodi A, Young E, Cooper A, Lidchi V, Winchester B and Wraith JE (1999) Long-term follow-up following bone marrow transplantation for Hunter disease. J Inherit Metab Dis 22:638-648.
51. Vieira T, Schwartz I, Munoz V, Pinto L, Steiner C, Ribeiro M, Boy R, Ferraz V, de Paula A, Kim C, et al. (2008) Muco-polysaccharidoses in Brazil: what happens from birth to biochemical diagnosis? Am J Med Genet A 146A:1741-1747.
52. Wraith JE, Beck M, Giugliani R, Clarke J, Martin R and Muenzer J (2008a) Initial report from the Hunter Outcome Survey. Genet Med 10:508-516.
53. Wraith JE, Scarpa M, Beck M, Bodamer OA, De Meirleir L, Guffon N, Meldgaard Lund A, Malm G, Van der Ploeg AT and Zeman J (2008b) Mucopolysaccharidosis type II (Hunter syndrome): a clinical review and recommendations for treatment in the era of enzyme replacement therapy. Eur J Pediatr 167:267-277.